Estimation of the Serum Ischemia Modified Albumin (IMA) and B-Type Natriuretic Peptide (BNP) Levels in Adult Beta-Thalassemia Major Patients in Baghdad-Iraq

Abstract

Background: Beta thalassemia major (β-T) is a prevalent genetic disorder worldwide that arises from a lack of globin chains. Ischemia-modified albumin (IMA) is a variant of the albumin protein that is produced in response to oxidative stress. It serves as a blood biomarker for tissue damage and myocardial ischemia. Cardiovascular disease is a widespread global health issue that results in mortality. In order to effectively prevent disease progression and administer appropriate treatment, it is crucial to diagnose the condition in its early stages by examining the extent of cardiac damage.

Objective: to quantify the levels of IMA in patients with β-thalassemia major (β-T) and compare them to those of healthy individuals. Additionally, we aim to evaluate the correlation between IMA levels and BNP.

Methods: Sixty participants were enrolled in this study in order to assess their serum IMA levels. 30 Beta-Thalassemia Major patients and 30 healthy individuals were included in this investigation, all of whom showed no signs of heart disease. The ELISA method was employed to determine the levels of serum IMA and BNP.

Results: Serum IMA and BNP increased in Beta-Thalassemia Major patients when compared with control healthy subjects (P < 0.001). There was no correlation between serum IMA and BNP in the patients’ group.